ST gliptin M 100/1000 Tablets provide an established, clinically unified combination therapy carefully developed for the continuous management and glycemic stabilization of Type 2 Diabetes Mellitus. When lifestyle adjustments alone are insufficient to maintain optimal hemoglobin $A_{1c}$ ($HbA_{1c}$) baselines, a multi-mechanistic approach is vital to address pancreatic dysfunction and peripheral insulin resistance simultaneously. This advanced oral formulation integrates two complementary anti-hyperglycemic agents within a single unit, maximizing therapeutic output while avoiding blood sugar fluctuations.
The formula operates dynamically across two distinct physiological fronts:
-
Sitagliptin (100 mg): A potent and highly selective dipeptidyl peptidase-4 ($DPP-4$) inhibitor. It functions by protecting active incretin hormones, including glucagon-like peptide-1 ($GLP-1$) and glucose-dependent insulinotropic polypeptide ($GIP$), from enzymatic degradation. By preserving these hormones, Sitagliptin systematically increases glucose-dependent insulin secretion from pancreatic beta cells while concurrently suppressing inappropriate glucagon secretion from alpha cells, lowering glucose output from hepatic pathways.
-
Metformin Hydrochloride (1000 mg SR): A foundational biguanide presented in a specialized Sustained Release (SR) matrix. Metformin acts primarily by reducing hepatic gluconeogenesis, decreasing intestinal glucose absorption, and enhancing peripheral glucose uptake and utilization by increasing insulin receptor sensitivity. The sustained-release layout ensures slow, uniform dissolution throughout the gastrointestinal tract, minimizing initial stomach tracking challenges and offering stable baseline regulation.
Together, ST gliptin M 100/1000 coordinates multi-front metabolic protection, helping you maintain complete daily glycemic control safely.
Key Benefits
-
Synergistic Glycemic Control: Combines pancreatic optimization with peripheral insulin enhancement for a comprehensive response to sugar spikes.
-
Sustained Release Matrix: Engineered to release Metformin gradually, drastically reducing gastric irritation or bloating common to standard formulas.
-
Weight-Neutral Management: Does not promote progressive weight gain, supporting healthy metabolic maintenance and body composition balance.
-
Low Hypoglycemia Profile: Works in harmony with your body’s natural glucose levels, minimizing the risk of sudden, dangerous low blood sugar crashes.
-
Trusted Quality: Manufactured under the strict pharmaceutical quality control benchmarks of Steris Healthcare, ensuring precise dosing uniformity.
Directions for Use
-
Take exactly as directed by your endocrinologist, diabetologist, or primary care physician.
-
Swallow the tablet whole with a full glass of water. Do not crush, break, or chew it, as doing so will compromise the specialized sustained-release mechanism.
-
ST gliptin M 100/1000 must strictly be taken orally with or immediately after a main meal (typically dinner or your heaviest meal) to maximize intestinal tolerance and reduce stomach discomfort metrics.
-
Maintain complete daily consistency alongside a portion-controlled diet and steady physical movement to monitor optimal therapeutic blood panels.
Safety & Precautions
-
Do not modify your dose or halt usage suddenly without professional medical clearance, as blood sugar levels can rise rapidly.
-
Lactic Acidosis Warning: Although rare, metformin-containing products can cause a serious metabolic complication known as lactic acidosis, particularly in patients with severe renal impairment. Inform your specialist immediately if you experience deep, rapid breathing, severe muscle cramps, or extreme unusual fatigue.
-
Inform your specialist before initialization if you have an underlying history of moderate-to-severe kidney disease (e.g., eGFR tracking boundaries), liver impairment, congestive heart failure, or a history of pancreatitis.
-
Avoid Excessive Alcohol Consumption: Limit or avoid alcohol while on this routine, as it can intensify initial gastric parameters and multiply the underlying tracking risk of lactic acidosis or hypoglycemia.
-
Routine monitoring of kidney function (serum creatinine / eGFR) and blood glucose trends is highly recommended during long-term care management.
-
Keep out of reach of children.
Storage
-
Store in a cool, dry place below 30°C.
-
Protect from direct sunlight, excessive heat sources, and environmental room moisture pools.
-
Keep the tablets safely stored inside their original protective packaging configuration until the exact moment of consumption.
